Table 2.

Relevant concomitant medication prohibited during the trial. Their use should be monitored at each monthly visit during the study treatment up until the first follow-up visit

Medication

- Methadone - Antibiotics: chloramphenicol, clarithromycin, doxycycline, dapsone - Antifungals: fluconazole, itraconazole, ketoconazole - Anticonvulsants: barbiturates, phenytoin, carbamazepine and sodium valproate - Antiarrhythmics: disopyramide, mexiletine, quinidine, tocainide - Anticoagulant: warfarin - Benzodiazepines: diazepam, lorazepam, etc. - Immunosuppressives: cyclosporine, tacrolimus, corticosteroids - Hormonal contraceptives: Because RPT may compromise the activity of oral contraceptives, a barrier method should be used in addition to oral contraceptives for sexually active female subjects of childbearing age - Haloperidol and newer generation of antipsychotics like risperidone and olazepine - Levothyroxine - Sildenafil (Viagra) - Theophylline - General anaesthetics - Ethanol can exacerbate the potential hepatoxicity of INH and rifamycins. Participants should be urged to abstain from alcohol while on study phase therapy